Authors:
Nafziger, AN
Erb, TA
Jenkins, PL
Lewis, C
Pearson, TA
Citation: An. Nafziger et al., The Otsego-Schoharie healthy heart program: prevention of cardiovascular disease in the rural US, SCAND J P H, 2001, pp. 21-32
Authors:
Nafziger, AN
Weinehall, L
Lewis, C
Jenkins, PL
Erb, TA
Pearson, TA
Wall, S
Citation: An. Nafziger et al., Design issues in the combination of international data from two rural community cardiovascular intervention programs, SCAND J P H, 2001, pp. 33-39
Authors:
Jenkins, PL
Weinehall, L
Erb, TA
Lewis, C
Nafziger, AN
Pearson, TA
Wall, S
Citation: Pl. Jenkins et al., The Norsjo-Cooperstown healthy heart project: A case study combining data from different studies without the use of meta-analysis, SCAND J P H, 2001, pp. 40-45
Authors:
Weinehall, L
Lewis, C
Nafziger, AN
Jenkins, PL
Erb, TA
Pearson, TA
Wall, S
Citation: L. Weinehall et al., Different outcomes for different interventions with different focus! A cross-country comparison of community interventions in rural Swedish and US populations, SCAND J P H, 2001, pp. 46-58
Authors:
Streetman, DS
Kashuba, ADM
Bertino, JS
Kulawy, R
Rocci, ML
Nafziger, AN
Citation: Ds. Streetman et al., Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping, PHARMACOGEN, 11(4), 2001, pp. 349-355
Authors:
Streetman, DS
Nafziger, AN
Destache, CJ
Bertino, JS
Citation: Ds. Streetman et al., Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs, PHARMACOTHE, 21(4), 2001, pp. 443-451
Authors:
Kim, JS
Nafziger, AN
Gaedigk, A
Dickmann, LJ
Rettie, AE
Bertino, JS
Citation: Js. Kim et al., Effects of oral vitamin K on S- and R-Warfarin pharmacokinetics and pharmacodynamics: Enhanced safety of warfarin as a CYP2C9 probe, J CLIN PHAR, 41(7), 2001, pp. 715-722
Authors:
McNamara, DR
Nafziger, AN
Menhinick, AM
Bertino, JS
Citation: Dr. Mcnamara et al., A dose-ranging study of gentamicin pharmacokinetics: Implications for extended interval aminoglycoside therapy, J CLIN PHAR, 41(4), 2001, pp. 374-377
Citation: Ds. Streetman et al., Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes, PHARMACOGEN, 10(3), 2000, pp. 187-216
Authors:
Amsden, GW
Nafziger, AN
Foulds, G
Cabelus, LJ
Citation: Gw. Amsden et al., A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers, J CLIN PHAR, 40(12), 2000, pp. 1522-1527
Authors:
Streetman, DS
Bleakley, JF
Kim, JS
Nafziger, AN
Leeder, JS
Gaedigk, A
Gotschall, R
Kearns, GL
Bertino, JS
Citation: Ds. Streetman et al., Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail", CLIN PHARM, 68(4), 2000, pp. 375-383
Authors:
Keyser, LA
Karl, M
Nafziger, AN
Bertino, JS
Citation: La. Keyser et al., Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients, ARCH IN MED, 160(10), 2000, pp. 1485-1488
Citation: Sa. Mcconnell et al., Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers, J ANTIMICRO, 43(5), 1999, pp. 733-736
Authors:
Nafziger, AN
Bertino, JS
GossBley, AI
Kashuba, ADM
Citation: An. Nafziger et al., Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy (vol 60, pg 187, 1999), J CLIN PSY, 60(5), 1999, pp. 341-341
Authors:
Nafziger, AN
Bertino, JS
Goss-Bley, AI
Kashuba, ADM
Citation: An. Nafziger et al., Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction - Reply, J CLIN PSY, 60(12), 1999, pp. 867-868
Authors:
Garey, KW
Peloquin, CA
Godo, PG
Nafziger, AN
Amsden, GW
Citation: Kw. Garey et al., Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers, ANTIM AG CH, 43(5), 1999, pp. 1152-1155
Authors:
Kashuba, ADM
Nafziger, AN
Drusano, GL
Bertino, JS
Citation: Adm. Kashuba et al., Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria, ANTIM AG CH, 43(3), 1999, pp. 623-629
Citation: Gw. Amsden et al., Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects, ANTIM AG CH, 43(1), 1999, pp. 163-165